Transcranial optical imaging reveals a pathway for optimizing the delivery of immunotherapeutics to the brain.
JCI Insight
; 3(20)2018 10 18.
Article
em En
| MEDLINE
| ID: mdl-30333324
ABSTRACT
Despite the initial promise of immunotherapy for CNS disease, multiple recent clinical trials have failed. This may be due in part to characteristically low penetration of antibodies to cerebrospinal fluid (CSF) and brain parenchyma, resulting in poor target engagement. We here utilized transcranial macroscopic imaging to noninvasively evaluate in vivo delivery pathways of CSF fluorescent tracers. Tracers in CSF proved to be distributed through a brain-wide network of periarterial spaces, previously denoted as the glymphatic system. CSF tracer entry was enhanced approximately 3-fold by increasing plasma osmolality without disruption of the blood-brain barrier. Further, plasma hyperosmolality overrode the inhibition of glymphatic transport that characterizes the awake state and reversed glymphatic suppression in a mouse model of Alzheimer's disease. Plasma hyperosmolality enhanced the delivery of an amyloid-ß (Aß) antibody, obtaining a 5-fold increase in antibody binding to Aß plaques. Thus, manipulation of glymphatic activity may represent a novel strategy for improving penetration of therapeutic antibodies to the CNS.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Líquido Cefalorraquidiano
/
Peptídeos beta-Amiloides
/
Doença de Alzheimer
/
Sistema Glinfático
/
Imunoterapia
Tipo de estudo:
Prognostic_studies
Limite:
Animals
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article